Navigation Links
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
Date:11/5/2011

  • A retrospective examination of real-world practice habits indicated that there is a disconnect between EU gout treatment guidelines and current practice patterns among rheumatologists and primary care physicians in the United States (U.S.). The analysis found that with the availability of oral conventional urate-lowering therapies (ULTs), 64 percent of rheumatologists' patients and 70 percent of primary care physicians' patients had uric acid levels greater than 6 mg/dL; an indicator that their gout was not adequately controlled. In addition, 37.5 percent of patients in rheumatology practices and 14.2 percent of patients in primary care practices had tophi. These data suggest that patients under the care of rheumatologists had higher disease burden than those under the care of primary care physicians.

  • Results from a survey of 620 gout patients in the U.S. and select EU countries, including France, Germany, Italy, Spain and the United Kingdom, showed that patients with higher uric acid levels also reported the presence of tophi and experienced an increased number of gout flares.  Patients with tophi endured a greater disease burden compared to those without the deposits, including: greater overall work productivity loss (40.2 percent vs. 21.2 percent), activity impairment (48.7 percent vs. 37.2 percent), and more physician visits (9.0 vs. 6.5) (p<0.05 for all). Further, gout flares also impacted patients' mental and physical well-being. Patients reported a greater deterioration in their quality of life in correlation with the number of gout flares they experienced, as well as work- and social-related impairment.

  • Information from a U.S. database analysis of 24,503 gout patients underscored the link between gout symptom severity and the physical and economic cost to the patient.  According to the analysis, patients with tophi who experienced greater than or equal to 3 gout flares during the study had significantly more ph
    '/>"/>

    • SOURCE Savient Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
    2. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
    3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
    4. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
    5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
    6. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
    7. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
    8. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
    9. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
    10. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
    11. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
    (Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
    (Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
    Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
    (Date:5/20/2013)... (PRWEB) May 20, 2013 According to a ... Warnings at Indoor Tanning Salons,” tanning salons in ... The Food and Drug Administration wants to see cancer warnings ... a minimum age floor of eighteen for the use of ... concerns about melanoma, which has become increasingly common over the ...
    (Date:5/20/2013)... According to a June 2009 Bloomberg article, ... amount to approximately $3.6 billion dollars per year (i). ... estimated that there 15 million incidents of medical harm ... everyone who receives any form of medical treatment should ... Merriam-Webster defines malpractice as “a dereliction of professional duty ...
    (Date:5/20/2013)... Osborn’s Brain: Imaging, Pathology, and ... Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. “The ... neuroradiology texts. , In this highly anticipated 1,300-page ... complex topics visually appealing and easy to understand. It ... with spectacular pathology examples, relevant anatomy, and the most ...
    (Date:5/20/2013)... Galveston researchers have been awarded a five-year, $1.8 million ... Stroke to apply the techniques of gene therapy to ... that arises from a malfunction in the nervous system. ... millions of Americans, manifesting itself in a variety of ... intense discomfort in response to a light touch, for ...
    (Date:5/20/2013)... 20, 2013 Horizon NJ Health, New ... announced that it has earned a Commendable Accreditation ... Horizon NJ Health is a wholly owned subsidiary of ... , NCQA Health Plan Accreditation is a nationally recognized ... that health plans provide to their members. Health Plan ...
    Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
    ... HIV positive girls will participate ,A beauty contest with ... 2005, which is the World AIDS Day, in which only ... ‘Miss Positive-2005’. The object of the contest is to change ... and also help HIV infected people lead a normal life. ...
    ... to two genes, both variant forms of a gene called ... in the smoking addiction.// The protein product of these genes ... the body. ,The two identified gene forms are ... metabolism of nicotine, more specifically found to account for slow ...
    ... heart failure patients in United States have better short-term ... over time.// ,Their study findings appear in the ... ,Heart failure is the most common cause of hospitalization ... ,The authors compared process of care and 30-day ...
    ... effective treatment option for patients with liver cancer. A ... to treat a patient who harbors a liver tumor ... surgical options are currently available for this group of ... the researchers who have now suggested a novel plan ...
    ... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
    ... (QBI) have now found a process that could lead ... and acquired brain injury. ,The research focuses on ... memory function and where the brain's ability to regenerate ... ,The study by Dr Natalie Bull and Professor ...
    Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2Health News:Research Targets treatment for dementia and brain injuries 2
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Each handle is designed to fit a specific trephine size....
    Medicine Products: